In the reanalysis, we found that patients with grade IV brain tumour (GBM), constituting the majority of group of the study cohort, exhibited a significantly increased IFN-γ response to MPF and mesothelin precursor peptide pool if the PBMCS were conditioned with IL-2/IL-15/IL-21 (Figure 3A). The gene discussed is IL15; the disease is glioblastoma.